WBC insulin-mediating role offers hope to diabetics
London: Neutrophils, an abundant type of white blood cell typically tasked with attacking bacteria and other foreign invaders, also plays an unexpected role in mediating insulin resistance – the central characteristic of type 2 diabetes.
This is the finding of researchers at the University of California, San Diego School of Medicine.
Neutrophils are the first immune cells to respond to tissue inflammation, and can promote chronic inflammation by summoning other white blood cells called macrophages. Chronic low-grade inflammation – common in adipose or fat tissue – is an important cause of systemic insulin resistance.
Using liver and fat cells from mice and humans and live mouse models, a team led by Jerrold M. Olefsky, MD, associate dean for scientific affairs at UC San Diego Health Sciences and professor of medicine, discovered that an enzyme secreted by neutrophils called neutrophil elastase (NE) impairs insulin signaling and boosts resistance. Conversely, deletion of NE in obese mice fed a high-fat diet improved insulin sensitivity.
“These results are largely unexpected. Although several immune cells have been established in the etiology of insulin resistance, the role of neutrophils in this process has remained unclear until now,” said Da Young Oh, an assistant project scientist in Olefsky’s lab and study co-author.
Oh said neutrophils were considered to be “transient infiltrates,” temporary cells (average lifespan: 5 days) that were incapable of sustaining chronic, low-grade inflammation.
“Our studies now suggest neutrophils possess powerful immune modulatory effects,” Oh said.
Specifically neutrophils use NE to activate a signaling pathway, which triggers pathogen-eating macrophages to secrete proinflammatory molecules called cytokines.
NE degrades IRS1, a key protein in the insulin signaling pathway in both liver and fat cells. Although NE has been shown to degrade this protein in lung cancer cells, the scientists said, the effect on insulin target tissues such as liver and adipose is striking.
The insulin-mediating role of neutrophils makes them a new target for developing treatments of insulin resistance in particular and diabetes in general.
“Given that NE mediates insulin resistance, one could, in theory, take an NE activity inhibitory approach to reverse or improve insulin resistance,” Oh said, noting that NE inhibitors are already used for treatment of emphysema in Japan and are being tested in the United States, both for emphysema and type 1 diabetes.
The findings have been published in the Advance Online Publication of Nature Medicine.